Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib

Lung Cancer

Volumn 52, Issue 2, 2006, Pages 253-255

  Nakatomi, Katsumi ^a,b   Soda, Hiroshi ^b   Kitazaki, Takeshi ^b   Nakano, Hirofumi ^b   Uchida, Kanako ^c   Urabe, Sou ^c   Nakamura, Yoichi ^b   Hayashi, Tomayoshi ^d   Tsukamoto, Kazuhiro ^c   Kohno, Shigeru ^b  

^a Nagasaki Prefectural Shimabara Hospital   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Epidermal growth factor; Lung cancer; Molecular targeted therapy; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; EXON; FEMALE; FOLLOW UP; GENE DELETION; HUMAN; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIOSURGERY; STEREOTAXIC SURGERY; SURVIVAL TIME; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TIME FACTORS;

EID: 33645999695     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.01.008     Document Type: Article

References (9)

1. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 556-568
2. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer). Lancet 366 (2005) 1527-1537
3. Hanna N., Shephered F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
4. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
5. Han S., Kim T., Hwang P.G., Jeong S., Kim J., Choi I.S., et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23 (2005) 2493-2501
6. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 6829-6837
7. Goto K., Kim Y.H., Kubota K., Niho S., Kakinuma H., Ohmatsu K., et al. Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol (2004) 22 [abstract #7098]
8. Phillips R.J., Mestas J., Gharaee-Kermani M., Burdick M.D., Sica A., Belperio J.A., et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammarian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1 alpha. J Biol Chem 280 (2005) 22473-22481
9. Kurata T., Tamura K., Kaneda H., Nogami T., Uejima H., Asai G., et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann Oncol 15 (2004) 173-177